ORGANIC AMIDE COMPOUNDS DERIVED FROM NITROGENOUS LIPIDS

Abstract: Organic amide compounds of the formula: wherein: R₁-CO is a residue of a carboxylic acid with the proviso that the carboxylic acid is not a natural fatty acid normally bound to nitrogen of nitrogenous lipids, R₁ is a hydrogen atom, a C₁₋₇ alkyl group, or a C₄₋₇ cycloalkyl group, and R 3-N a residue of a nitrogenous lipid. The compounds are useful in increasing or stimulating the in vivo biological activity of in vitro biologically active carboxylic acids.

Description: The present invention relates to the use of an organic amide compound, for the manufacture of a pharmaceutical product for the treatment of disorders of the central or peripheral nervous system as well as to the new compounds belonging to this family and to the pharmaceutical compositions containing these new compounds. It more precisely concerns a family of organic amide compounds to be used for the manufacture of a pharmaceutical product for the treatment of the central or peripheral nervous system in vivo; it also concerns the new compounds belonging to this family as well as the pharmaceutical compositions containing them. Numerous compounds are known to be active in vitro and yet exhibit little or no activity in vivo. In particular, numerous carboxylic acids are known to be important in the actions of the peripheral and central nervous systems and are active in vitro but are either non-active or only slightly active in vivo. Gamma-aminobutyric acid (GABA), for example, is known to be active on the central nervous system in vitro and has been suggested as a possible inhibitory transmittor (Louis S. Goodman and Alfred Gilman, The Pharmacological Basis of Therapeutics, 4th Ed., p. 429 (1970)). However, GABA has been found to be ineffective when administered in vivo as measured by convulsion tests in mice. Further US-P-4 129 650 describes the use of phospholipid derivatives to lowering blood pressure and is restricted to the use of such derivatives where at least one of the R₁ and R₂ substituents is a fatty acid radical. Chemical abstracts 68 (1978) 87545g discloses compounds to be used as prototypes for biological studies of bioactive phosphatidopeptides; no specific pharmaceutical properties are described in said reference. In CA 95 (1981) 81537 are described muramylpeptides presenting immunopotentializing properties and in CA 66 (1967) prototypes of biological active phosphatidopeptides with alanine or glycyl substituents are described. None of these references concern however the enhanced and direct action on the central or peripheral nervous system in vivo and more precisely the use for the prevention of convulsive states and the treatment of behavorial alterations resulting from modifications of neuropeptide hormones of compounds according to the present invention. The present inventors have found that compounds of the formula (I), prepared by combining a carboxylic acid, such as GABA, with a phospholipid or sphingolipid, provide amide compounds which are active in vivo exhibiting activities far superior to that of the corresponding carboxylic acid or lipid compounds administered alone. For example, the amide of GABA with a sphingosine provides a compound which is far more active in vivo than is GABA alone. Similarly, lysergic acid, dihydrolysergic acid and isolysergic acid are essentially inactive when administered alone, but when combined with a sphingosine provide compounds of the formula (I) which have significant in vivo activity as measured by hypoprolactinemic effects in rats. The significantly improved pharmacological properties of the compounds of formula (I) are thought to result from the ability of these compounds to penetrate the hematoencephalic barrier and/or reach the peripheral organs far better than the carboxylic acid compounds alone. This ability of the compounds of the present invention favors the interaction between the biologically active compound, such as the carboxylic acid, and the situs of the specific interactions present in the membranes. Hence, the compounds of the present invention are useful for enhancing or increasing the in vivo biological activity of in vitro biologically active carboxylic acids, as well as stimulating the in vivo biological activity of in vitro biologically active carboxylic acids which have little or no in vivo activity, so that they can be used therapeutically as pharmaceutical products for the treatment of disorders of the central or peripheral nervous system. The present invention concerns more specifically the use of an organic amide compound for the manufacture of a pharmaceutical product for the treatment of disorders of the central or peripheral nervous system, said organic amide compound having the formula: wherein: R₁ - CO is an acyl radical of a per se known carboxylic acid having a known, potentially therapeutic, biological action on the central or peripheral nervous system in vitro, excluding natural fatty acids and esters derived from hydroxy substituted natural fatty acid groups linked to nitrogen of natural phospholipids or sphingolipids and excluding benzenecarboxylic acids and esters derived therefrom and prostaglandins but not excluding trimethoxybenzoic acid and esters derived therefrom; R₂ is a hydrogen atom, a C₁₋₇ alkyl group or C₄₋₇ cycloalkyl group; and R₃ - N is a residue of a phospholipid or sphingolipid, or the pharmaceutically acceptable salts thereof. The invention also concerns the organic amide compound of the formula wherein: R₁ - CO is an acyl radical of a carboxylic acid selected from lysergic, isolysergic, dihydrolysergic, 2-bromolysergic, 2-bromodihydrolysergic, 1-methyllysergic, 1-methyldihydrolysergic, 1-methyl-2-bromolysergic, 1-methyl-2-bromodihydrolysergic, gamma-aminobutyric, valproic, trimethoxy-benzoic, nicotinic, isonicotinic, picolinic and theophyllineacetic acids; R₂ is a hydrogen atom, a C₁₋₇ alkyl group or C₄₋₇ cycloalkyl group; and R₃ - N is a residue of a phospholipid or sphingolipid, or the pharmaceutically acceptable salts thereof. The invention also concerns, more generally, pharmaceutical compositions containing as active substance, an organic amide compound such as defined here above. Natural fatty acids and esters derived from hydroxy substituted natural fatty acid groups linked to nitrogen of natural phospholipids or shingolipids are described in, for example: Wiegandt, Adv. in Lipid Res. , Vol. 9, pp. 249-288, Ed. by Paoletti and Kritchezsky (Academic Press, 1971), and Ansell and Hawthorne, Phospholipids , Biochem. Biophys. Acta. Library, Vol. 3, pp. 420-425 (Elsevier Pub. Co., 1964). The R₁-COOH acids which give rise to the R₁-CO residue are those acids which are fundamentally important to the peripheral and central nervous systems, such as lysergic, isolysergic, dihydrolysergic, 2-bromolysergic, 2-bromodihydrolysergic, 1-methyllysergic, 1-methyldihydrolysergic, 1-methyl-2-bromo-lysergic, 1-methyl-2-bromodihydrolysergic, gamma-aminobutyric, valproic (2-propylpentanoic), trimethoxybenzoic, nicotinic, isonicotinic, picolinic and theophyllineacetic acids. These acids have the common pharmaceutical characteristic of being active in vitro but non-active or only slightly active in vivo . R₂ may be a hydrogen atom or an alkyl having from 1 to 7 carbon atoms such as butyl, isobutyl, tertiarybutyl, propyl, isopropyl, ethyl, and methyl or a cycloalkyl having from 4 to 7 carbon atoms, such as cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. The -N-R₃ residue is derived from a nitrogenous lipid, especially from phospholipids and sphingolipids. Phospholipids, natural products that can be extracted from bovine brain tissue, are chemically derived from L-α-glycerophosphoric acid. (Lees, M. B., Met. Enzymol , Vol. 3, pp. 328-345 (1957): Bigon et al, G. Brit. J. Pharmacol., Vol. 67, pp. 611-619 (1979); Spanner, Form and Function of Phospholipids, Ed. By Ansell et al, Biochem. Biophys. Acta. Library, Vol. 3 pp. 43-65 (1973)]. The two major phospholipid groups which are utilized are the phosphatidylethanolamines (II) and the phosphatidylserines (III) represented by the following structures: wherein: R and R′ represent a hydrogen atom or the acyl radical of an organic carboxylic acid, especially, the acyl radical of a saturated or unsaturated fatty acid. Sphingolipids are natural products extracted, in particular, from animals and vegetables and contain an amino-alcohol moiety [Dawson, Form and Function of Phospholipids, Ed. by Ansell et al, Biochem. Biophys. Acta. Library, Vol. 3, pp. 104-105 (1973); Kaller, Biochem. Zeitschrift, Vol. 334, pp. 451-456 (1961); Sweeley et al, J. Lipid, Res., Vol. 1, pp. 40-47 (1959); Radin, Lipids, Vol. 9, pp. 358-360 (1970)]. Especially preferred sphingosines are those having an average of 12 to 22 carbon atoms. The sphingolipid derivatives which permit the preparation of the compounds (I) of the present invention contain a sphingosinic residue and contain a free sphingosine -NH₂ group. Principally these are: Sphingosine represented by the formula: wherein: n may be from 6 to 16. Dihydrosphingosine represented by the formula: wherein: n may be from 8 to 18. Psychosine or galactosylsphingosine represented by the formula: wherein: n may be from 6 to 16. Dihydropsychosine represented by the formula: wherein: n may be from 8 to 18. Phosphorylcholine sphingosine or lysosphingomyelins represented by the formula: wherein: n may be from 6 to 16. Phosphorylcholine - dihydrosphingosine, or lysodihydrosphingomyelins represented by the formula: wherein: n may be from 8 to 18. Phytosphingosine represented by the formula: wherein: n may be from 11 to 15, and all other sphingolipids which through hydrolysis are capable of releasing an amine (-NH₂) group, such as is indicated below by the sphingomyelin formula (XI): Preparation Procedures The organic amides (I) according to the present invention can be prepared according to a variety of preparation methods under conditions which prevent the esterification of the free carboxy group. Of all the methods which have proved to be particularly appropriate, the following are most preferred: 1. The reaction between the R₁CON₃ azides (corresponding to the R₁-COOH acid) and the nitrogenous lipidic derivatives. The preparation of the R₁CON₃ azides can be realized by utilizing one of the known methods. 2. The acylimidazole preparation method comprising reacting the R₁COOH acid with N,N′-carbonyldiimidazole, followed by the reaction of the thus produced acylimidazole with the nitrogenous lipid. 3. The mixed anhydride preparation method comprising reacting the R₁COOH acid and trifluoracetic acid to form a mixed anhydride and then reacting the mixed anhydride with the nitrogenous lipid. 4. Preparing the chloride of the R₁COOH acid followed by reacting the chloride with the nitrogenous lipid. 5. Direct reaction between the R₁COOH acid and the nitrogenous lipid in the presence of a carbodiimide (for example N,N′-dicyclohexylcarbodiimide, N-benzyl-N′-isopropylcarbodiimide or N-benzyl-N′-ethylcarbodiimide) or another substance similar to 1-hydroxybenzotriazole. 6. Direct condensation by heating the R₁COOH acid with the nitrogenous lipidic derivatives. 7. Direct reaction between the methyl ester of the R₁COOH acid and the nitrogenous lipidic derivative; this reaction is favored by heating. 8. Preparation of an ester by reacting a R₁COOH acid with a phenol (for example, para-nitrophenol) followed by the reaction of the ester with the nitrogenous lipid. The ester preparation between the acid and a phenol can be realized by using one of the known methods. In the preparation of the products described in formula (I) derived from gamma-aminobutyric acid, the method preferably used is that consisting of the initial preparation of a gamma-aminobutyric derivative where the amino group is protected, as for example, by a phthaloyl or benzyloxycarbonyl group. The derivative thus prepared is then further condensed with the nitrogenous lipid using one of the reactions previously described. The protective group is then eliminated by means of an appropriate reaction and the product (I) is thus obtained. For example, if the protective group is phthaloyl, this group could be eliminated by hydrazinalysis. The compounds of formula (I), wherein the R₁-COOH acid contains a basic group (for example, gamma-aminobutyric, nicotinic, lysergic or dihydrolysergic acid), can be salified with therapeutically acceptable acids such as: hydrochloric, hydrobromic, methanesulphonic and malic acids. As described above, according to the present invention, numerous compounds, particularly carboxylic acids, can be combined with nitrogenous lipids to produce amide compounds which are pharmaceutically active in vivo . Although not limiting, the following examples illustrate the products, preparation procedures and pharmaceutical preparations of the present invention. Example 1 Product 1 Gamma-aminobutyrylsphingosine amides of the formula: a - A gamma-phthalmidobutyryl-sphingosine-amide (Product 1a) is prepared as follows: 5.7 g of sphingosine (obtained from the sphingolipids present in the bovine brain and corresponding to a sphingosine C₁₈) are treated with 50 ml of absolute ethanol. 8.9 g of the para-nitrophenyl ester of the gamma-phthalmidobutyric acid (prepared according to: J. Org. Chem. 27, 684-696, 1962) are added to the solution. The solution is then heated and left to precipitate for 2 hours and the solvent is removed under vacuum. The residue is mixed with 500 ml of a methylene chloride ethanol mixture (4/1). The organic solution is dried on sodium sulphate, filtered and the solvent is then vacuum separated. The residue crystallizes from methylene chloride - n-hexane, M.P. 97°C, yield 7.3 g. Thin layer chromatography (silica gel) using a eluent mixture of methylene chloride/ethyl acetate/methanol (70/30/10), indicates that it is a single compound with Rf of 0.4. b - 5.14 g of the gamma-phthalamidobutyryl sphingosine-amide (Product 1a) are treated with 30 ml of absolute ethanol; 20 ml of an ethanolic solution of 1 Molar hydrazine are added and heated and allowed to precipitate for 2 hrs. The solvent is then evaporated in a vacuum and 50 ml of acetic acid (2 Normal) is added to the residue and heated for 10 minutes at 50°C. The mixture is left to cool to room temperature and filtered. The filtered solution is concentrated in vacuum and an aquoeus solution of NaOH (2N) is added until a clearly alkaline pH is obtained. The aqueous phase is extracted with a mixture of methylene chloride/ethanol (4/1). The organic solution is dried over sodium sulphate, filtered and evaporated. The residue crystallizes from tertiary-butyl methyl ether, and gamma-amino-butyryl-sphingosine amides (Product 1) M.P. 87°C, are thus obtained (yield 3.1 g). Thin layer chromatography (silica gel) using an eluent mixture formed by chloroform/methanol/water/ammonia concentrated aqueous solution (70/35/5/1) indicates that the Product 1 is a single compound with Rf of 0.16. Example 2 Products 2.1 and 2.2 Isolisergylsphingosine amides of the formula: and lysergylsphingosine amides, an isomer from the formula (2.1), of the formula: 6.7 g of D-lysergic acid are treated with 400 ml of dimethylformamide (DMF) (this reaction is conducted taking care to work away from light); the lysergic acid gradually forms a solution. 4.45 g of N,N′-carbonyldiimidazole dissolved in 125 ml of DMF are added to the solution and kept at room temperature for 2 hours. 8.25 g of sphingosine (obtained from the sphingolipids present in the bovine brain and corresponding to a sphingosine C₁₈) are added and the mixture is maintained at room temperature for 24 hours. DMF is evaporated in vacuum and the residue is treated with 1000 ml of ethyl acetate, the suspension is filtered and the organic solution washed with 5M ammonia and then with water. The organic solution is dried over sodium sulphate and then filtered and evaporated thus obtaining a residue. The residue is then chromatographically fractionated separating the two compounds: Product 2.1; Product 2.2. a - Product 2.1-Isolysergylsphingosine-amide Chromatography on silica gel plates using an eluent mixture of ethyl acetate/methanol (80/20), indicates that it is a single compound with Rf 0.74. Evaluation of the specific rotating power is carried out in methanol solution (1%) using a 1 dm polarimetric tube - result is (α) D = +235°. b - Product 2.2-Lysergylsphingosine-amide (crystallizes from acetone M.P. 139°C). Chromatography on silica gel plates using an eluent mixture of ethyl mixture of ethyl acetate/methanol (80/20) indicates that it is a single compound with Rf 0.30. Evaluation of a specific rotary power is carried out in 1 % chloroform using a 1 dm polarimetric tube - result is (α) D = +3. Example 3 Product 3 a - Dihydrolysergylsphingosine amide of the formula: 2.7 g of dihydrolysergic acid (prepared from catalytic hydrogenation of the lysergic acid) and 2.7 g of 1-hydroxybenzotriazole are added to 100 ml of chloroform. The mixture, under continual agitation, is brought to 30°C, after which 3 g of sphingosine (obtained from the sphingolipids present in the bovine brain and corresponding to a sphingosine C₁₈) and 2 g of N,N′-dicyclohexylcarbodiimide are added. The mixture is heated and allowed to precipitate for 1 hour, brought to room temperature and then 25 ml of ethanol are added. The organic solution is washed with 5M ammonia and then with water. The organic solution is vacuum dried, thus obtaining a residue and solubilized in 30 ml of methanol. The methanolic solution is brought to 0°C thus precipitating the dicyclohexylurea; the suspension is filtered and the solvent is eliminated from the filtered substance by vacuum. The residue is solubilized by heating with 45 ml of acetone. While cooling, the dihydrolysergylsphingosine amides crystallize, M.P. 206°C, yield 3.8 g. Thin layer chromatography (silica gel) using an eluent mixture of methylene chloride/ethyl acetate/methanol (60/30/15), indicates that it is a single compound with Rf of 0.25. Evaluation of a specific rotary power is carried out in a 2% methanol solution using a 1 dm polarimetric tube : result is (α) D = -63°. b - The preparation of the salt with methanesulfonic acid from the dihydrolysergyl sphingosine amide is as follows: 1 g of dihydrolysergyl sphingosine amide is dissolved in 50 ml of acetone, 0.18 g of methane-sulphonic acid are added. The solution is then concentrated to a small volume with crystallizing the salt of the dihydrolysergylsphingosine amides with methane sulphonic acid. Evaluation of a specific rotary power is carried out in a methanol solution of 2% using a 1 dm polarimetric tube - result is (α) D = -41.5°. Example 4 Product 4 Valproylsphingosine amide of the formula: 11.5 g of sphingosine (taken from the sphingolipids present in the bovine brain and corresponding to a sphingosine C₁₈) are treated with 1000 ml of absolute ethanol. To this solution 13.1 g of the paranitrophenyl ester of valproic acid [prepared according to: Chim. Ther. 3 , (5) 336-42, (1968)] is added. This solution is then treated as for that described in Example 5. The residue is crystallized by tertiarybutyl methyl ether, M.P. 118°C, yield 14.9 g. Thin layer chromatography (silica gel) utilizing an eluent mixture formed from: methylene chloride/ethyl acetate/methanol (70/30/10), indicates that it is a single compound with Rf 0.85. Example 5 Product 5 3,4,5-Trimethoxybenzoylsphingosine amide of the formula: 5 g of sphingosine (taken from the sphingolipids present in the bovine brain and corresponding to a sphingosine C₁₈) are treated with 500 ml of absolute ethanol. To this solution 7.35 g of a p-nitrophenyl ester of the 3,4,5-trimethoxybenzoic acid are added [prepared according to: Anales Asoc. Guim. Argentina 26 , 51-56, (1938)]. This mixture is heated and left to precipitate for 2 hours and the solvent is removed under vacuum. The residue is mixed with 500 ml of a methylene chloride/ethanol mixture (4/1). The organic solution is washed with an aqueous solution of sodium carbonate and then with water. The organic solution is dried on sodium sulphate, filtered and the solvent is then vacuum separated. The residue crystallizes from tertiarylbutyl methyl ether, M.P. 130°C, yield 7.3 g. Thin layer chromatography (silica gel) using an eluent mixture formed by methylene chloride/ethyl acetate/methanol (40/30/10), indicates that it is a single compound with Rf of 0.5. Example 6 Product 6 7-Theophyllinacetylsphingosine amide of the formula: 6 g of sphingosine (taken from the sphingolipids present in the bovine brain and corresponding to a sphingosine C₁₈) are treated with 500 ml of absolute ethanol. To this solution are added 9.5 g of a p-nitrophenylester of 7-theophyllineacetic acid [prepared according to: Annalen (1976) 860-75]. The same procedure as described in Example 5 is then followed. The residue crystallizes from methanol, M.P. 189°C, yield 8.5 g. Thin layer chromatography (silica gel) using an eluent mixture formed by methylene chloride/ethyl acetate/methanol (60/30/20), indicates that it is a single compound with Rf of 0.6. Example 7 Product 7 Nicotinylsphingosine amide of the formula: 5 g of sphingosine (obtained from the sphingolipids present in the bovine brain and corresponding to a sphingosine C₁₈) are treated with 500 ml of absolute ethanol. 5.5 g of p-nitrophenyl ester of the nicotinic acid are added to the solution [prepared according to: J. Chem. Soc. B. (1971) 2401-6]. The same procedure as described in Example 5 is then followed. The residue crystallizes from tertiary-butyl methyl ether, M.P. 105°C, yield 6.7 g. Thin layer chromatography (silica gel) using an eluent mixture formed by methylene chloride/ethyl acetate/methanol (70/30/10) indicates that it is a single compound with an Rf of 0.23. Example 8 Product 8 3,4,5-Trimethoxybenzoylpsycosine amide of the formula: 5 g of psycosine (taken from the sphingolipids present in the bovine brain and corresponding to a sphingosine C₁₈ are treated with 4.8 g of the p-nitrophenyl ester of 3,4,5-trimethoxybenzole acid in an ethanolic solution (see Example 5). The same procedure as described in Example 5 is then followed. The residue crystallizes from ethanol - acetone, M.P. 135°C, yield 6.7 g. Thin layer chromatography (silica gel) using an eluent mixture formed by chloroform/methanol/water (110/40/6), indicates that it is a single compound with Rf of 0.85. Example 9 Product 9 Nicotinylpsycosine amide of the formula: 5 g of psycosine (obtained from the sphingolipids present in the bovine brain and corresponding to a sphingosine C₁₈) are treated with 3.5 g of the p-nitrophenyl ester of nicotinic acid in an ethanolic solution (see Example 7). The same procedure as described in Example 5 is then followed. The residue crystallizes from acetone, M.P. 140°C, yield 6.7 g. Thin layer chromatography (silica gel) using an eluent mixture formed by chloroform/methanol/water (110/40/6), indicates that it is a single compound with an Rf of 0.80. Example 10 Product 10 3,4,5-Trimethoxybenzoyl-sphingosinephosphorylcholine amide of the formula: 5 g of sphingosinephosphorylcholine (taken from the sphingolipids present in the bovine brain and corresponding to a sphingosine C₁₈) are treated with 4.6 g of a p-nitrophenyl ester of the 3,4,5-trimethoxybenzoic acid in an ethanolic solution (see Example 5). The same procedure as described in Example 5 is then followed. The residue crystallizes from tertiary-butyl methyl ether, M.P. 127°C, yield 6.1 g. Thin layer chromatography (silica gel) using an eluent mixture formed by chloroform/methanol/water (60/35/8), indicates that it is a single compound with a Rf of 0.25. Example 11 Product 11 3,4,5-Trimethoxybenzoyl-phosphatidylserine amide of the formula: 5 g of phosphatidylserine (taken from the phospholipids present in the bovine brain and in which the groups R and R′ are mainly stearoyl, palmitoyl, oleoyl, linolenoyl, linoleoyl and arachidonoyl radicals) are treated with 2.8 g of a p-nitrophenyl ester of 3,4,5-trimethoxybenzoic acid in an ethanolic solution (see Example 5). The same procedure as described in Example 5 is then followed, excluding the wash of the organic solution with Na₂CO₃. The residue is purified by chromatography, yield 4.5 g. Thin layer chromatography (silica gel) using an eluent mixture formed by chloroform/methanol/water (70/30/5), indicates that it is a single compound with an Rf of 0.5. Example 12 Product 12 Nicotinylphosphatidylserine amide of the formula: 5 g of phosphatidylserine (taken from the phospholipids present in the bovine brain and in which the groups R and R′ are mainly stearoyl, palmitoyl, oleoyl, linolenoyl, linoleoyl and arachidonoyl radicals) are treated with 2 g of a p-nitrophenyl ester of nicotinic acid in an ethanolic solution (see Example 7). The same procedure as described in Example 5 is then followed, excluding the wash of the organic solution with Na₂CO₃. The residue is purified by chromatography, yield 5.1 g. Thin layer chromatography (silica gel) using an eluent mixture formed by chloroform/methanol/water (70/35/5), indicates that it is a single compound with an Rf of 0.5. Example 13 Product 13 3,4,5-Trimethoxybenzoyl-isophosphatidylserine amide of the formula: 5 g of lisophosphtidylserine (taken from the enzymatic hydrolysis of phosphatidylserine, the R group in the lisophosphatidylserine being mainly stearoyl or oleoyl radicals) are treated with 4.3 g of a p-nitrophenyl ester of 3,4,5-trimethoxybenzoic acid in an ethanolic solution (see Example 5). The same procedure as described in Example 5 is then followed, excluding the wash of the organic solution with Na₂CO₃. The residue is purified by chromatography, yield 6.0 g. Thin layer chromatography (silica gel) using an eluent mixture formed by chloroform/methanol/water (60/35/8), indicates that it is a single compound with an Rf of 0.3. Example 14 Product 14 3,4,5-Trimethoxybenzoylphosphatidylethanolamine amide of the formula: 5 g of phosphatidylethanolamine (taken from the phospholipids present in the bovine brain and in which the groups R and R′ are mainly oleoyl, stearloyl, palmitoyl, linoleoyl and arachidonoyl acid radicals) are treated with 3 g of a p-nitrophenyl ester of 3,4,5-trimethoxybenzoic acid in an ethanolic solution (see Example 5). The same procedure as described in Example 5 is then followed. The residue is purified by chromatography, yield 5.1 g. Thin layer chromatography (silica gel) using an eluent mixture formed by methylene chlorine/ethyl acetate/methanol (70/30/20), indicates that it is a single compound with an Rf of 0.30. Example 15 Product 15 Dihydrolysergyldihydrosphingosine amide of the formula: The procedure is carried out as described in Example 3, beginning with 2.5 g of dihydrosphingosine (obtained through the catalytical hydrogenation of the sphingosine C₁₈); 2.24 g of dihydrolysergic acid; 2.24 g of 1-hydroxybenzotriazole; and 2.06 g of N,N′-dicyclohexylcarbodiimide. The reaction takes place in chloroform (130 ml). The compound crystallizes from acetone, M.P. 200°C, yield 3.6 g. Thin layer chromatography (silica gel) using an eluent mixture formed by chloroform/methanol/ammonia 1N (64/24/3.2), indicates that it is a single compound with an Rf of 0.69. Evaluation of the specific rotary power is carried out in a 2% methanol solution using a 1 dm polarimetric tube. Results: (α) D = -47.5°. Example 16 Product 16 Dihydrolysergylpsychosine amide of the formula: The procedure is carried out as described in Example 3, beginning with 2.8 g of psychosine (obtained from the sphingolipids present in the bovine brain and containing a sphingosinic residue C₁₈); 1.62 g of dihydrolysergic acid; 1.62 g of 1-hydroxybenzotriazole; and 2.06 g of N,N′-dicyclohexylcarbodiimide. The reaction takes place in a chloroform solution 100 ml of chloroform. The compound crystallizes from ethyl acetate, M.P. 140°C, yield 3.8 g. Thin layer chromatography (silica gel) using an eluent mixture formed by chloroform/methanol/ammonia 1N (64/24/3.2), indicates that it is a single compound with an Rf of 0.43. Evaluation of the specific rotary power is carried out in a 2% methanol solution using a 1 dm polarimetric tube. Results: (α) D = -32°. Example 17 Products 17.1 and 17.2 Isolysergylpsychosine amide of the formula: and lysergylpsychosine amide of the formula: The procedure is carried out as described in Example 2, beginning with 6.7 g of D-lysergic acid; 4.45 g of N,N′-carbonyldiimidazol, 12.7 g of psychosine (taken from sphingolipids present in the bovine brain and containing a sphingosinic residue C₁₈). The reaction takes place in a dimethylformamide solution of the same volume as described in Example 2. The residue is then chromatographically fractionated separating the two compounds: Product 17.1 and Product 17.2. a - Product 17.1 - isolysergyl psychosine amide, M.P. 97°-100°C. Chromatography on silica gel using an eluent mixture formed by chloroform/methanol/ammonia 1M (64/24/3.2), indicates that it is a single compound with Rf 0.76. Evaluation of the specific rotary power is carried out in a 2% methanol solution using a 1 dm polarimetric tube. Results: (α) D = + 143°. b - Product 17.2 - lysergylpsychosine amide, M.P. 122°-126°C. Chromatography on silica gel using an eluent mixed formed by chloroform/methanol/ammonia 1M (64/24/3.2), indicates that it is a single compound with an Rf of 0.59. Evaluation of the specific rotary power is carried out in a 2% methanol solution using a 1 dm polarimetric tube. Results: (α) D = +2°. Example 18 Product 18 Isonicotinylsphingosine amide of the formula: 5 g of sphingosine (taken from the sphingolipids present in the bovine brain and corresponding to a sphingosine C₁₈) are treated with 500 ml absolute ethanol. To the solution, 5.5 g of the p-nitrophenyl ester of isonicotinic acid [prepared according to: C.A. 59 , 8708b (1963)] is added. The same procedure as described in Example 5 is then followed. The residue crystallizes from acetonitrile, M.P. 116°C, yield 6.0 g. Thin layer chromatography (silica gel) using an eluent mixture formed by methylene chloride/ethyl acetate/methanol (70/30/15), indicates that it is a single compound with an Rf of 0.49. Pharmacological Properties The compounds described above in Examples 1, 2, 3, 15 and 16 were tested for pharmacological activity. These compounds were tested both in vitro and in vivo in laboratory animals and proved to be capable of acting directly on the central nervous system. Product 1 of Example 1 - Gamma-aminobutyrylsphingosine amide a. in vitro tests: Gamma-aminobutyric acid (GABA), NH₂(CH₃)₃-CO₂H, is an endogenous substance and is biologically active due to interaction with a specific receptor but is incapable, by itself, of penetrating the encephalic barrier. Accordingly, GABA has been found to be active in vitro but relatively inactive in vivo . The compounds of the present invention, on the other hand, are active both in vitro and in vivo . To show this activity of the compounds of the present invention, in vitro tests measuring the binding levels of radioactive gamma-aminobutyric acid, ³H-GABA, on synaptic membranes of the rat cortex were carried out according to the method of Enna and Snyder [Enna, S. J. and Snyder, S. H., Mol. Pharmacol. 13 , 442-353 (1977)]. Table I, herein after, presents the results of these tests, expressed in percentage of the fixed active product, comparing the in vitro activity of Product 1 with the activities of the individual components which comprise Product 1. The results show that sphingosine alone exhibits no biological activity while GAB alone exhibits activity comparable to that of Product 1. b. in vivo tests: The in vivo activity of Product 1 was measured by the method described by Costa et al [E. Costa, A. Guidotti and C. C. Mao; "Evidence for involvement of GABA in the Action of Benzodiazepines: Studies in Rat Cerebellum" in Mechanism of action of Benzodiazepines ; Ed. by E. Costa and P. Greengard, New York, Raven Press. pp. 113-130 (1975)] and by Loescher and Frey [Loesher, W. and Frey, H. H.; "Effect of convulsant and anticonvulsant agents on level and metabolism of gamma-aminobutyric acid in mouse brain"; Naunyn-Schmiedeberg's Arch. Pharmacol. 296, 263-269 (1977)]. These tests are based on the known activity of isoniazide to cause convulsions and a lowering of the GABA cerebral levels and the glutamic-decarboxylase enzyme activity. According to the test method, isoniazide is administered to the control animals (rats) while isoniazide and the appropriate test compound are administered to the groups of test animals and the results are measured in terms of the number of animals exhibiting convulsions, the latency of convulsions and the number of deaths. The results are presented in Table II, herein-above, and show that Product 1 has far superior in vivo activity as compared to GABA or shingosine alone. Product 3 of Example 3 - Dihydrolysergylsphinsoine amide a. in vitro tests: The in vitro biological activity was determined by comparative tests measuring the binding power of the labeled spiroperidole (³H)-spiroperidole on hypophysis sinaptosomal rat membranes according to the method described by Greese et al [Greese I., Schneider R. and Snyder S. H.; "H-spiroperidole labels dopamine receptors in pituitary and brain"; Europ. J. Pharmacol. 46 , 377-381 (1977)]. The results obtained and illustrated in Table III, herein-after, show that the binding power of Product 3 is significant and far superior, under the same experimental conditions, to that of dihydrolysergic acid or sphingosine alone. b. in vivo tests: The in vivo biological activity of Product 3 was measured by evaluating the serum levels of prolactin in hyperprolactinemic animals according to the RIA method (radioimmunoassay) and the instructions in the NIAMDD program. The results obtained and illustrated in Table IV, herein-above, expressed as % of inhibition, show that Product 3 exhibits significant biological activity, especially as compared to the weak effect of dihydrolysergic acid. Product 15 of Example 15 - Dihydrolysergyldihydrosphinsoine amide The in vitro biological activity and in vivo activities of Product 15 were evaluated according to the same methods as used above for Product 3 of Example 3. The results obtained and presented in Tables V and VI show the in vitro and in vivo activities of Product 15 to be far superior to either dihydrolysergic acid or dihydrosphingosine alone. Product 2.2 of Example 2 - Lysergylsphingosine amide The in vitro and in vivo biological activities of Product 2.2 were evaluated according to the same methods as described above for Product 3, Example 3. The results obtained and presented in Tables VII and VIII show the in vitro and in vivo activities of Product 2.2 to be far superior to either lysergic acid or sphingosine alone. Product 16 of Example 16 - Dihydrolisergylpsychosine amide The in vitro and in vivo biological activities of Product 16 were evaluated according to the same methods as described for Product 3, Example 3. The results obtained and presented in Tables IX and X show that in vitro and in vivo activities of Product 16 to be far superior to either dihydrolysergic acid or psychosine alone. Therapeutic Uses According to the present invention, the organic amides derived from nitrogenous lipids can be used as medicaments for various therapeutic uses, in particular for those uses corresponding to the activities of the active acids from which the amides are prepared. For example, derivatives of lysergic, isolysergic, dihydrolysergic, 2-bromolysergic, 2-bromo-dihydrolysergic, 1-methyl-lysergic, 1-methyl-dihydrolysergic, 1-methyl-2-bromolysergic, 1-methyl-2-bromodihydrolysergic, gamma-aminobutyric, valproic, trimethoxybenzoic and nicotininc acid are suitable for use as medicaments capable of exhibiting pharmacological activity on the central nervous system. The derivatives of lysergic acid, 2-bromolysergic, 1 -methyllysergic and 1-methyl-2-bromolysergic also exert a significant activity on the uterus. Specifically, the compounds of the present invention which are experimentally active against insoniazid convulsions and on the binding of GABA in vitro , and the pharmaceutical compositions containing them, may be therapeutically useful in pathologies connected with changes in the function of the GABAurgic system, since these products are able to enhance levels of GABA in the central nervous system (CNS) and in the specific cerebal areas, thereby enabling the GABA, bound to natural amino-alcohols, to penetrate the blood-brain barrier. To be more precise, these compounds and the pharmaceutical preparations containing them may be usefully employed in the prevention of convulsive states which usually give rise to tonoclonic contractions and/or loss of consciousness, as in epilepsy; that is, in focal epilepsy, in psychomotorial epilepsy, in major epilepsy, in idiopathic epilepsy, in status epilipticus and in centroencephalic epilepsy (in minor epilepsy, akinetic attacks, mioclonic epilepsy) and in general, in pathologies deriving from decrease of inhibitoru control in the CNS. The compounds which have proved to be active in inhibiting the serum levels of prolactin and in the blinding in vitro of the dopaminergic ligand in the hypophysis, and the pharmaceutical compositions deriving from them, as exemplified in the in vivo and in vitro data noted above, may be usefully employed in pathologies which present alterations in the release of neuropeptides from hypophysis as prolactin due to changes in the regulation of the neurotransmittor system with loss of dopaminergic system tonic inhibition or, in general, of the hypothalmic routes as in hyperprolactinemias caused by neuroleptics such as sulpiride chlorpromazine, etc. Thus, the drugs deriving from the compounds of the present invention may be used in the treatment of behavioral alterations resulting from modifications of neuropeptide hormones from hypophysis as hyperprolactinemic syndromes with loss of lipids and impotence, and hypopituitarism with changes in personality, apathy, indifference, astenia, loss of lipido and confusion, and premenstural syndromes with depression and changes of mood and climacteric syndromes with variations in mood, irritability, anxiety, nervousness and depression. The compounds of the present invention can be administered as pharmaceutical compositions containing, as an active ingredient, one or more of the amides in association with one or more compatible and pharmaceutically acceptable excipients. The compositions can be administered via various administration routes, such as injectable solutions, tablets, gelatine capsules and suppositories. The dosage administered will vary depending upon the desired effect and administration route, but, for example, in oral administration the dosages can be between 10 and 300 mg of active substance per day with a single dosage of from 10 to 100 mg. The following are examples of pharmaceutical compositions for oral administration: a. Pharmaceutical preparation 1: 10 mg tablets Each tablet contains: - Active substance 10 mg - Microcrystalline cellulose 100 mg - Lactose 150 mg - Magnesium stearate 2.5 mg - Starch 20 mg b. Pharmaceutical preparation 2: 50 mg tablets Each tablet contains: - Active substance 50 mg - Microcrystalline cellulose 100 mg - Lactose 110 mg - Magnesium stearate 2.5 mg - Starch 20 mg c. Pharmaceutical preparation 3: 100 mg tablets Each tablet contains: - Active substance 100 mg - Microcrystalline cellulose 100 mg - Lactose 2.5 mg - Magnesium stearate 3.5 mg - Starch 25 mg d. Pharmaceutical preparation 4: 10 mg gelatine capsule Each capsule contains: - Active substance 10 mg - Vegetable oil 100 mg - Gelatine 100 mg - Glycerine 25 mg e. Pharmaceutical preparation 5: 50 mg gelatine capsule Each capsule contains: - Active substance 50 mg - Vegetable oil 120 mg - Gelatine 110 mg - Glycerine 30 mg f. Pharmaceutical preparation 6: 100 mg gelatine capsule Each capsule contains: - Active substance 100 mg - Vegetable oil 150 mg - Gelatine 130 mg - Glycerine 44 mg

Claims: Use of an organic amide compound for the manufacture of a pharmaceutical product for the treatment of disorders of the central or peripheral nervous system, said organic amide compound having the formula wherein: R₁ - CO is an acyl radical of a per se known carboxylic acid having a known, potentially therapeutic, biological action on the central or peripheral nervous system in vitro , excluding natural fatty acids and esters derived from hydroxy substituted natural fatty acid groups linked to nitrogen of natural phospholipids or sphingolipids and excluding benzenecarboxylic acids and esters derived therefrom and prostaglandins but not excluding trimethoxybenzoic acid and esters derived therefrom; R₂ is a hydrogen atom, a C₁₋₇ alkyl group or C₄₋₇ cycloalkyl group; and R₃ - N is a residue of a phospholipid or sphingolipid, or the pharmaceutically acceptable salts thereof. Use according to claim 1, wherein R₂ represents a hydrogen atom. Use according to claim 1 or 2, wherein said phospholipid is a phosphatidylethanolamine or a phosphatidylserine. Use according to claim 1 or 2, wherein said sphingolipid is sphingosine or a sphingosine derivative having from 12 to 22 carbon atoms. Use according to claim 4, wherein said sphingolipid is selected from dihydrosphingosine, psychosine, dihydropsychosine, sphingosinephosphorylcholine, dihydrosphingosinephosphorylcholine and phytosphingosine. Use according to claim 4, wherein R₂ represents a hydrogen atom, said lipid is sphingosine and said carboxylic acid is selected from gamma-aminobutyric acid, lysergic acid, isolysergic acid, dihydrolysergic acid, valproic acid, 3,4,5-trimethoxybenzoic acid, 7-theophyllineacetic acid, nicotinic acid and isonicotinic acid. Use according to claim 5, wherein R₂ represents a hydrogen atom, said lipid is psychosine and said carboxylic acid is selected from 3,4,5-trimethoxybenzoic acid, nicotinic acid, dihydrolysergic acid, lysergic acid and isolysergic acid. Use according to claim 5, wherein R₂ represents a hydrogen atom, said lipid is sphingosine-phosphorylcholine and said carboxylic acid is 3,4,5-trimethoxybenzoic acid. Use according to claim 5, wherein R₂ represents a hydrogen atom, said lipid is dihydrosphingosine and said carboxylic acid is dihydrolysergic acid. An organic amide compound of the formula wherein: R₁ - CO is an acyl radical of a carboxylic acid selected from lysergic, isolysergic, dihydrolysergic, 2-bromolysergic, 2-bromodihydrolysergic, 1-méthyllysergic, 1-méthyldihydrolysergic, 1-methyl-2-bromolysergic, 1-methyl-2-bromodihydrolysergic, gamma-aminobutyric, valproic, trimethoxy-benzoic, nicotinic, isonicotinic, picolinic and theophyllineacetic acids; R₂ is a hydrogen atom, a C₁₋₇ alkyl group or C₄₋₇ cycloalkyl group; and R₃ - N is a residue of a phospholipid or sphingolipid, or the pharmaceutically acceptable salts thereof, An organic amide compound according to claim 10, wherein R₂ represents a hydrogen atom. An organic amide compound according to claim 10 or 11, wherein said phospholipid is a phosphatidylethanolamine or a phosphatidylserine. An organic amide compound according to claim 10 or 11, wherein said sphingolipid is sphingosine or a sphingosine derivative having from 12 to 22 carbon atoms. An organic amide compound according to any one of claims 10, 11 or 13 wherein said sphingolipid is selected from sphingosine, dihydrosphingosine, psychosine, dihydropsychosine, sphingosinephosphorylcholine, dihydrosphingosinephosphorylcholine and phytosphingosine. An organic amide compound according to any one of claims 10, 11 or 13 wherein R₂ represents a hydrogen atom, said lipid is sphingosine and said carboxylic acid is selected from gamma-aminobutyric acid, lysergic acid, isolysergic acid, dihydrolysergic acid, valproic acid, 3,4,5-trimethoxybenzoic acid, 7-theophyllineacetic acid, nicotinic acid and isonicotinic acid. An organic amide compound according to any one of claims 10, 11, 13 or 14 wherein R₂ represents a hydrogen atom, said lipid is psychosine and said carboxylic acid is selected from 3,4,5-trimethoxybenzoic acid, nicotinic acid, dihydrolysergic acid, lysergic acid and isolysergic acid. An organic amide compound according to any one of claim 10, 11, 13 or 14 wherein R₂ represents a hydrogen atom, said lipid is sphingosine-phosphorylcholine and said carboxylic acid is 3,4,5-trimethoxybenzoic acid. An organic amide compound according to any one of claims 10, 11, 13 or 14 wherein R₂ represents a hydrogen atom, said lipid is dihydrosphingosine and said carboxylic acid is dihydrolysergic acid. An organic amide compound according to claim 10, which consists in a 3,4,5-trimethoxybenzoylphosphatidylserine amide of the formula: wherein R and R′ are saturated or unsaturated fatty acid acyl radicals. An organic amide compound according to claim 10, which consists in a nicotinylphosphatidinylserine amide of the formula: wherein R and R′ are saturated or unsaturated fatty acid acyl radicals. An organic amide compound according to claim 19 or 20, wherein the R and R′ groups are selected from stearoyl, palmitoyl, oleoyl, linolenoyl, linoleoyl and arachidonyl radicals. An organic amide compound according to claim 10, which consists in a 3,4,5-trimethoxybenzoylisophosphatidylserine amide of the formula: wherein R is a saturated or unsaturated fatty acid acyl radical. An organic amide compound according to claim 22, wherein R is a stearoyl or oleoyl radical. An organic amide compound according to any one of claims 10 to 12, which consists in a 3,4,5-trimethoxybenzoylphosphatidinylethanolamine amide of the formula: wherein R and R′ are saturated fatty acid acyl radicals. An organic amide compound according to claim 24, wherein R and R′ are selected from oleoyl, stearoyl, palmitoyl, linoleoyl and arachidonyl radicals. A pharmaceutical composition containing, as active substance, an organic amide compound of the formula wherein: R₁ - CO is an acyl radical of a carboxylic acid selected from lysergic, isolysergic, dihydrolysergic, 2-bromolysergic, 2-bromodihydrolysergic, 1-methyllysergic, 1-methyldihydrolysergic, 1-methyl-2-bromolysergic, 1-methyl-2-bromodihydrolysergic, gamma-aminobutyric, valproic, trimethoxy-benzoic, nicotinic, isonicotinic, picolinic and theophyllineacetic acids; R₂ is a hydrogen atom, a C₁₋₇ alkyl group or C₄₋₇ cycloalkyl group; and R₃ - N is a residue of a phospholipid or sphingolipid, or the pharmaceutically acceptable salts thereof. A pharmaceutical composition according to claim 26, wherein R₂ represents a hydrogen atom. A pharmaceutical composition according to claim 26 or 27, wherein said phospholipid is a phosphatidylethanolamine or a phosphatidylserine. A pharmaceutical composition according to claim 26 or 27, wherein said sphingolipid is sphingosine or a sphingosine derivative having from 12 to 22 carbon atoms. A pharmaceutical composition according to claim 27, wherein said sphingolipid is selected from dihydrosphingosine, psychosine, dihydropsychosine, sphingosinephosphorylcholine, dihydrosphingosinephosphorylcholine and phytosphingosine. A pharmaceutical composition according to claim 29, wherein R₂ represents a hydrogen atom, said lipid is sphingosine and said carboxylic acid is selected from gamma-aminobutyric acid, lysergic acid, isolysergic acid, dihydrolysergic acid, valproic acid, 3,4,5-trimethoxybenzoic acid, 7-theophyllineacetic acid, nicotinic acid and isonicotinic acid. A pharmaceutical composition according to any one of claims 26, 27, 29 or 30, wherein R₂ represents a hydrogen atom, said lipid is psychosine and said carboxylic acid is selected from 3,4,5-trimethoxybenzoic acid, nicotinic acid, dihydrolysergic acid, lysergic acid and isolysergic acid. A pharmaceutical composition according to any one of claims 26, 27, 29 or 30, wherein R₂ represents a hydrogen atom, said lipid is sphingosine-phosphorylcholine and said carboxylic acid is 3,4,5-trimethoxybenzoic acid. A pharmaceutical composition according to any one of claims 26, 27, 29 or 30 wherein R₂ represents a hydrogen atom, said lipid is dihydrosphingosine and said carboxylic acid is dihydrolysergic acid. A pharmaceutical composition according to claim 26, which contains a 3,4,5-trimethoxybenzoylphosphatidylserine amide of the formula: wherein R and R′ are saturated or unsaturated fatty acid acyl radicals. A pharmaceutical composition according to claim 26, which contains a nicotinylphosphatidinylserine amide of the formula: wherein R and R′ are saturated or unsaturated fatty acid acyl radicals. A pharmaceutical composition according to claim 35, wherein the R and R′ groups are selected from stearoyl, palmitoyl, oleoyl, linolenoyl, linoleoyl and arachidonyl radicals. A pharmaceutical composition according to claim 26, which contains a 3,4,5-trimethoxybenzoylisophosphatidylserine amide of the formula: wherein R is saturated or unsaturated fatty acid aryl radical. A pharmaceutical composition according to claim 38, wherein R is a stearoyl or oleoyl radical. A pharmaceutical composition according to claim 26, which contains a 3,4,5-trimethoxybenzoylphosphatidinylethanolamine amide of the formula: wherein R and R′ are saturated fatty acid acyl radicals. A pharmaceutical composition according to claim 40, wherein R and R′ are selected from oleoyl, stearoyl, palmitoyl, linoleoyl and arachidonyl radicals. For pharmaceutical use an organic amide compound consisting in any one of the compounds according to claims 10 to 25.

Inventors: DELLA VALLE, FRANCESCO, ROMEO, AURELIO
Applicants: FIDIA S.P.A.
Application year: 1982
Main classification: C07H15
IPC codes: C07D457, C07C237, C07C235, A61K31, C07F9, C07D213, C07C233, A61P25, C07H15, C07D473, C07C231, A61P43